Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.41 |
| ▸ | FEN1 | P39748 | 1/20 | 0.41 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.40 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.40 |
| ▸ | NOS3 | P29474 | 2/20 | 0.40 |
| ▸ | NOS1 | P29475 | 2/20 | 0.40 |
| ▸ | NOS2 | P35228 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4790717 | 1.00 | POLB (0.47) | POLBL3MBTL1MAPTNPSR1PIK3CA | |
| SCHEMBL2894993 | 0.80 | NOS3 (0.44) | MAPTPIK3CAMTORP2RX3P2RX2 | |
| SCHEMBL29637494 | 0.80 | NOS3 (0.44) | MAPTPIK3CAMTORP2RX3P2RX2 | |
| SCHEMBL29637497 | 0.80 | NOS3 (0.44) | MAPTPIK3CAMTORP2RX3P2RX2 | |
| SCHEMBL15527772 | 0.80 | LMNA (0.41) | POLBL3MBTL1MAPTNOS3NOS1 | |
| SCHEMBL15577744 | 0.80 | AXL (0.46) | POLBL3MBTL1MAPTNPSR1PIK3CA | |
| SCHEMBL22234714 | 0.79 | ALOX5AP (0.38) | MAPTNPSR1ALOX5APFEN1P2RX3 | |
| Bromide SCHEMBL19950848 | 0.79 | LMNA (0.40) | POLBL3MBTL1MAPTNOS3NOS1 | |
| SCHEMBL15933053 | 0.78 | AXL (0.43) | POLBL3MBTL1MAPTNPSR1AXL | |
| SCHEMBL10200160 | 0.77 | AXL (0.42) | POLBL3MBTL1MAPTNPSR1AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4518974-A1 | IMIDAZO(1,2-A)PYRIDINE DERIVATIVES AS RIPK2 INHIBITORS | Interline Therapeutics, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| CN-118955497-A | Imidazo [1,2-a ] pyridine IRAK4 degradation agent and application thereof | 泰诺瑞(天津)生物科技有限责任公司 | 2024-11-15 | — | — | CN | disclosed |
| US-RE49931-E1 | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-04-23 | — | — | US | disclosed |
| US-RE49893-E1 | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-04-02 | — | — | US | disclosed |
| US-RE49880-E1 | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-03-26 | — | — | US | disclosed |
| WO-2023239941-A1 | IMIDAZO(1,2-A)PYRIDINE DERIVATIVES AS RIPK2 INHIBITORS | INTERLINE THERAPEUTICS INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-11672780-B2 | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-06-13 | — | — | US | disclosed |
| US-20220296573-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2022-09-22 | — | — | US | disclosed |
| US-20220194938-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2022-06-23 | — | — | US | disclosed |
| EP-3947377-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Galapagos N.V. (BE) | 2022-02-09 | — | — | EP | disclosed |
| EP-3947374-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Galapagos N.V. (BE) | 2022-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11672780-B2 | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds | TLR7, TLR1, TLR5 | POLB 3282/4885L3MBTL1 4400/4885MAPT 3696/4885 |
| US-20220296573-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | LTB4R2, LTC4S, LTB4R | POLB 3110/4885L3MBTL1 4832/4885MAPT 4185/4885 |
| US-20220194938-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | LTB4R2, LTC4S, CYSLTR1 | POLB 3273/4885L3MBTL1 4677/4885MAPT 4242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.